PNTG Healthcare

The Pennant Group, Inc.

$41.19+1.70%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Medical Care Facilities
Country: United States
Market cap: 1.4B USD
Enterprise value: 1.6B USD
Full-time employees: 9,700

Overall health

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.27 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.20 vs a peer median of 2.59)higher risk: bigger price swings (beta 1.27 vs peers 0.63) and less liquidity (current ratio 1.20 vs peers 2.59)
About average: profitability and valuation

Ranks #552 of 1,157 healthcare companies (top 48%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 18% from December 2022 to August 2026.
Pennant had 18% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Pennant had 18% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Profits growing faster than sales. Since 2022: revenue +100%, operating profit +307%.
Since 2022, Pennant's revenue grew 100% while operating profit grew 307%: each extra dollar of sales is adding more profit.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $391M in 2020 to $948M in 2025.
Pennant's fiscal-year revenue rose in each of the five years to 2025, from $391M to $948M.
Profit is backed by cash. Free cash flow is 107% of reported profit.
Pennant's free cash flow is 107% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

53/ 100

Oct 5 54 → Nov 4 53 (-1)

Valuation

Is the price right?

52/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Close to the peer norm on every measure.

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield2.2%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 0.52Sector median: 0.0148 · MAD: 0.0148

EBITDA yield4.5%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 0.11Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield2.4%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield28.1%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

83/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 7.7%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth
▲ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth19.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.32Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth30.0%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 2.87Sector median: 0.0584 · MAD: 0.0840

Revenue growth37.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 3.26Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

56/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Helped by:

▲ ROIC
▲ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin5.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.12Sector median: 0.0706 · MAD: 0.1217

Return on assets3.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.27Sector median: 0.0166 · MAD: 0.0537

Return on invested capital8.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.37Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin19.6%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity8.0%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Current ratio
▼ Beta
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.27

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.91Sector median: 0.6250 · MAD: 0.3380

Current ratio1.20×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.00Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.48×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.25Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Pennant

Is Pennant getting weaker?: Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 53/100 since Oct 28, 2026.
How is Pennant valued vs its peers?: Priced about in line with its peers. Valuation scores 52/100 against 1,393 healthcare peers.
Is Pennant growing?: Yes, faster than most of its peers. Growth scores 83/100 against 1,393 healthcare peers. 3-year revenue growth 30.0% vs a peer median of 5.8% (stronger than 88% of peers).3-year revenue growth 30.0% vs peers 5.8% (stronger than 88% of peers).
How profitable is Pennant?: About as profitable as its peers. Profitability scores 56/100 against 1,393 healthcare peers. Return on invested capital 8.4% vs a peer median of 4.7% (stronger than 63% of peers).Return on invested capital 8.4% vs peers 4.7% (stronger than 63% of peers).
How risky is Pennant?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.20× vs a peer median of 2.59× (weaker than 84% of peers).Current ratio 1.20× vs peers 2.59× (weaker than 84% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	1.0B USD	1.1B USD	+7.7%
Net income (12 months)	30.3M USD	32.3M USD	+6.6%
Operating margin	5.5%	5.6%	+0.1 pts
Free cash flow (12 months)	50.8M USD	34.7M USD	−31.7%
Debt	164.7M USD	192.5M USD	+16.9%
Cash	4.9M USD	15.3M USD	+210.9%
Shares outstanding	34.8M	34.9M	+0.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Care Facilities · 27 companies

Valuations in Medical Care Facilities are within their usual range since Jun 2017.

39% of months since Jun 2017 were valued lower than now.
28% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is −61% vs the whole market, against a usual −56%.

Jun 2017Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	1.1%	2.7%	4.6%	5.5%	5.5%	▼ 0.0 pts
Net margin	0.6%	1.4%	2.5%	3.2%	3.1%	▼ 0.1 pts
Return on assets (ROA)	0.5%	1.3%	2.5%	3.3%	3.1%	▼ 0.3 pts
Return on equity (ROE)	2.4%	5.3%	9.2%	7.2%	7.9%	▲ 0.7 pts
Free cash flow margin	-5.6%	-1.1%	4.6%	4.4%	3.8%	▼ 0.5 pts
Current ratio	1.06×	1.05×	1.12×	1.21×	1.14×	▼ 5.9%
Debt to equity	0.45×	0.50×	0.44×	0.00×	0.45×	—
Interest coverage	2.42×	3.34×	4.25×	5.48×	7.77×	▲ 42%

PNTG price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.27 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.20 vs a peer median of 2.59)higher risk: bigger price swings (beta 1.27 vs peers 0.63) and less liquidity (current ratio 1.20 vs peers 2.59)

About average: profitability and valuation

Ranks #552 of 1,157 healthcare companies (top 48%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 18% from December 2022 to August 2026.

Pennant had 18% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Pennant had 18% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Profits growing faster than sales. Since 2022: revenue +100%, operating profit +307%.

Since 2022, Pennant's revenue grew 100% while operating profit grew 307%: each extra dollar of sales is adding more profit.

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $391M in 2020 to $948M in 2025.

Pennant's fiscal-year revenue rose in each of the five years to 2025, from $391M to $948M.

Profit is backed by cash. Free cash flow is 107% of reported profit.

Pennant's free cash flow is 107% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about Pennant

Is Pennant getting weaker?

Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 53/100 since Oct 28, 2026.

How is Pennant valued vs its peers?

Priced about in line with its peers. Valuation scores 52/100 against 1,393 healthcare peers.

Is Pennant growing?

Yes, faster than most of its peers. Growth scores 83/100 against 1,393 healthcare peers. 3-year revenue growth 30.0% vs a peer median of 5.8% (stronger than 88% of peers).3-year revenue growth 30.0% vs peers 5.8% (stronger than 88% of peers).

How profitable is Pennant?

About as profitable as its peers. Profitability scores 56/100 against 1,393 healthcare peers. Return on invested capital 8.4% vs a peer median of 4.7% (stronger than 63% of peers).Return on invested capital 8.4% vs peers 4.7% (stronger than 63% of peers).

How risky is Pennant?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.20× vs a peer median of 2.59× (weaker than 84% of peers).Current ratio 1.20× vs peers 2.59× (weaker than 84% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

1.0B USD

1.1B USD

+7.7%

Net income (12 months)

30.3M USD

32.3M USD

+6.6%

Operating margin

5.5%

5.6%

+0.1 pts

Free cash flow (12 months)

50.8M USD

34.7M USD

−31.7%

Debt

164.7M USD

192.5M USD

+16.9%

Cash

4.9M USD

15.3M USD

+210.9%

Shares outstanding

34.8M

34.9M

+0.5%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

1.1%

2.7%

4.6%

5.5%

▼ 0.0 pts

Net margin

0.6%

1.4%

2.5%

3.2%

3.1%

▼ 0.1 pts

Return on assets (ROA)

0.5%

1.3%

2.5%

3.3%

3.1%

▼ 0.3 pts

Return on equity (ROE)

2.4%

5.3%

9.2%

7.2%

7.9%

▲ 0.7 pts

Free cash flow margin

-5.6%

-1.1%

4.6%

4.4%

3.8%

▼ 0.5 pts

Current ratio

1.06×

1.05×

1.12×

1.21×

1.14×

▼ 5.9%

Debt to equity

0.45×

0.50×

0.44×

0.00×

0.45×

—

Interest coverage

2.42×

3.34×

4.25×

5.48×

7.77×

▲ 42%